axitinib

This page shows the latest axitinib news and features for those working in and with pharma, biotech and healthcare.

Keytruda combo outshines Opdivo in kidney cancer

s Inlyta (axitinib), shows it outperforming BMS’ pairing of Opdivo and Yervoy.

EU approval for Opdivo combo in renal cell cancer

VEGF-targeting Inlyta (axitinib).
Roche pulls EU Tecentriq/Avastin filing in kidney cancer

inhibitor Keytruda (pembrolizumab) from Merck &Co/MSD, including impressive survival data in combination with Pfizer’s Inlyta (axitinib) in the phase 3 KEYNOTE-426 trial reported at this year’s ESMO
BMS CEO tackles investor ‘frustrations’ on immuno-oncology

inhibitor Bavencio (avelumab) – both given in tandem with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib) – leading to them being touted as a potential new treatment standard for these patients.
Keytruda hits survival targets in first-line kidney cancer

s VEGF-targeting Inlyta (axitinib), showing that the duo improved overall survival (OS) and progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib).
Merck’s Bavencio joins first-line kidney cancer face-off

The JAVELIN Renal 101 study reported at this week’s ESMO conference paired Merck’s immuno-oncology drug Bavencio (avelumab) with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), and revealed a

More from news
Approximately 5 fully matching, plus 24 partially matching documents found.

Cancer immunotherapy: What's on the horizon?

They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Mirna hires former Pfizer director as CMO

Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Oncology drugs under AMNOG

Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!: EXCELLENT DAY RATES AVAILABLE

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Add my company

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...